Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Boostrix-IPV (sometimes referred to as Boostriv-IPV in specific clinical trial documentation) is a reduced-antigen combination vaccine designed to provide booster protection against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. Developed by GSK, it contains diphtheria toxoid, tetanus toxoid, three purified pertussis antigens (pertussis toxoid, filamentous haemagglutinin, and pertactin), and inactivated poliovirus types 1, 2, and 3. The vaccine is primarily indicated for use in adolescents and adults who have previously completed a primary vaccination series. In the United Kingdom, it was a central component of the "Multiboost" study conducted by the Health Protection Agency (HPA), which evaluated the immunogenicity and safety of co-administering dTaP-IPV with meningococcal serogroup C (MCC) conjugate vaccines and Haemophilus influenzae type b (Hib) vaccines. The vaccine works by stimulating the production of specific antibodies against the bacterial toxins and viral components, thereby inducing active immunity.
- Brand names
- Boostrix-IPVBoostriv-IPVRepevaxAdacel-Polio
- Other names
- dTaP-IPVreduced antigen diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine.